Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 May 2004, Vol. 103, No. 9, pp. 3547-3548.
Prepublished online as a Blood First Edition Paper on December 30, 2003; DOI 10.1182/blood-2003-10-3505.

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2003-10-3505v1
103/9/3547    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tefferi, A.
Right arrow Articles by Mesa, R. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tefferi, A.
Right arrow Articles by Mesa, R. A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted October 14, 2003
Accepted December 27, 2003

Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia

Ayalew Tefferi*, Terra L Lasho, Alexandra P Wolanskyj, and Ruben A Mesa

Hematology, Mayo Clinic, Rochester, MN, USA

* Corresponding author; email: tefferi.ayalew{at}mayo.edu.

Recent studies have demonstrated neutrophil over-expression of the PRV-1 gene in polycythemia vera (PV) but not in secondary or spurious polycythemia (SP). In order to validate as well as expand upon this novel observation, we conducted a prospective study of 88 subjects; 30 with PV, 22 with SP, 14 with essential thrombocythemia (ET), 12 with myelofibrosis with myeloid metaplasia (MMM), and 10 controls. In order to minimize inter-study methodological differences, we used published real-time PCR-based assay. The proportion of patients with increased neutrophil PRV-1 expression was 83% in PV, 21% in ET, 42% in MMM, 18% in SP, and 0% in controls. All 5 MMM patients with PRV-1 up-regulation had an antecedent history of PV. We conclude that neutrophil PRV-1 up-regulation is a characteristic feature of PV that may not be affected by fibrotic transformation. However, quantifying neutrophil PRV-1 mRNA, while complementary to other tests, is not self-sufficient for the diagnosis of PV.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
A. V. Jones, S. Kreil, K. Zoi, K. Waghorn, C. Curtis, L. Zhang, J. Score, R. Seear, A. J. Chase, F. H. Grand, et al.
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Blood, September 15, 2005; 106(6): 2162 - 2168.
[Abstract] [Full Text] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
S. Sirhan, T. L. Lasho, and A. Tefferi
Clinical and Laboratory Correlative Studies of Neutrophil PRV-1 Expression: A Prospective Study in 141 Subjects.
Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 1519 - 1519.
[Abstract] [Full Text]

Home page
 BloodHome page
L. Teofili, M. Martini, F. Guidi, D. Venditti, G. Leone, and M. L. Larocca
The PRV-1 gene expression in essential thrombocythemia
Blood, November 1, 2004; 104(9): 2995 - 2996.
[Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020